Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (22655)	1/4/2000 9:54:00 AM
From: OmertaSoldier	Read Replies (1) \| Respond to of 23519

Full news release............. Tuesday January 4, 8:10 am Eastern Time Company Press Release VIVUS Announces Resolution of the AstraZeneca Distribution Agreement MOUNTAIN VIEW, Calif.--(BW HealthWire)--Jan. 4, 2000--VIVUS International, Ltd. (a subsidiary of VIVUS, Inc.) (Nasdaq:VVUS - news) and AstraZeneca today announced the resolution of all financial obligations relating to the return to VIVUS of marketing and distribution rights for MUSE© (alprostadil) from AstraZeneca. AstraZeneca will continue to handle patient and physician inquiries and ensure product supply in all countries in which AstraZeneca currently markets MUSE. This support will be phased out during the next 12 months as VIVUS establishes new distribution partners in these markets. ``The resolution of financial obligations relating to this agreement will result in significantly increased revenues for the fourth quarter of 1999 and the first quarter of 2000,' said Leland F. Wilson, president and CEO of VIVUS, Inc. In addition, the company announced receipt of the marketing license for MUSE in Italy and will recognize $2.0 million in milestone revenue during the fourth quarter of 1999. VIVUS, Inc. is the developer and manufacturer of MUSE (alprostadil) and ACTIS(TM), two innovations in the treatment of men with erectile dysfunction (``ED'), also known as impotence. The Company's objective is to become a global leader in the development and commercialization of innovative therapies for the treatment of sexual dysfunction and urologic disorders in men and women. VIVUS has ongoing research and development programs in female sexual dysfunction and male premature ejaculation. The company recently filed a New Drug Application with the FDA for ALIBRA©, its second-generation male ED treatment. Note to editors and investors: Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719).